These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22678353)

  • 1. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
    Cella D; Butt Z; Kindler HL; Fuchs CS; Bray S; Barlev A; Oglesby A
    Qual Life Res; 2013 Jun; 22(5):1105-12. PubMed ID: 22678353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
    Kindler HL; Richards DA; Garbo LE; Garon EB; Stephenson JJ; Rocha-Lima CM; Safran H; Chan D; Kocs DM; Galimi F; McGreivy J; Bray SL; Hei Y; Feigal EG; Loh E; Fuchs CS
    Ann Oncol; 2012 Nov; 23(11):2834-2842. PubMed ID: 22700995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
    Moinpour CM; Vaught NL; Goldman B; Redman MW; Philip PA; Millwood B; Lippman SM; Seay TE; Flynn PJ; O'Reilly EM; Rowland KM; Wong RP; Benedetti J; Blanke CD
    J Clin Oncol; 2010 Aug; 28(22):3611-6. PubMed ID: 20606094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients.
    Degboe A; Ivanescu C; Rohay JM; Turner RR; Cella D
    Support Care Cancer; 2019 Nov; 27(11):4189-4198. PubMed ID: 30825026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire.
    Heffernan N; Cella D; Webster K; Odom L; Martone M; Passik S; Bookbinder M; Fong Y; Jarnagin W; Blumgart L
    J Clin Oncol; 2002 May; 20(9):2229-39. PubMed ID: 11980994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants.
    Maeda H; Sato M; Kobayashi M; Takiguchi N; Yoshikawa T; Yoshino S; Yoshida K; Tsuburaya A; Sakamoto J; Morita S
    Support Care Cancer; 2016 Nov; 24(11):4515-21. PubMed ID: 27272031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
    Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
    Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
    Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
    BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment of palliative radiotherapy for pancreatic cancer.
    Tian Q; Zhang F; Wang Y
    Cancer Radiother; 2018 Dec; 22(8):778-783. PubMed ID: 30401617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
    McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
    Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
    Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
    J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.
    Bharmal M; Nolte S; Henry-Szatkowski M; Hennessy M; Schlichting M
    Health Qual Life Outcomes; 2020 May; 18(1):145. PubMed ID: 32430019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status.
    Gmür A; Kolly P; Knöpfli M; Dufour JF
    Liver Int; 2018 Aug; 38(8):1468-1474. PubMed ID: 29389088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).
    Butt Z; Parikh ND; Beaumont JL; Rosenbloom SK; Syrjala KL; Abernethy AP; Benson AB; Cella D
    Cancer; 2012 Dec; 118(23):5997-6004. PubMed ID: 22605658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.
    Diouf M; Filleron T; Pointet AL; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Fein F; Dubreuil O; Landi B; Zaanan A; Taieb J; Bonnetain F
    Qual Life Res; 2016 Jul; 25(7):1713-23. PubMed ID: 26615615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.